SHR-1802 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P2 | N=25 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=124 ➔ 25 | Recruiting ➔ Terminated; Adjustment of R&D strategy

Enrollment change • Trial termination • Solid Tumor

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. (PubMed, Ther Adv Med Oncol) - P1 | "Further studies with larger sample size and in combination forms are warranted for future clinical application. NCT04414150."

Journal • Metastases • P1 data • PK/PD data • Hematological Disorders • Immune Modulation • Oncology • Solid Tumor

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=132 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2022

Trial completion • Trial completion date • Oncology • Solid Tumor

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | N=42 ➔ 28 | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Jun 2021 ➔ Jan 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P2 | N=124 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • CD4 • CD8

A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P2 | N=124 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Oncology • Solid Tumor • CD4 • CD8

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Clinical • New P1 trial • Oncology

Hengrui Medicine’s LAG-3 antibody wins clinical nod in China (GBI Health) - "The Center for Drug Evaluation (CDE) website indicates that SHR-1802, Jiangsu Hengrui Medicine Co., Ltd’s (600276.SH) in-house developed lymphocyte activation gene 3 protein (LAG-3, aka CD233), has won tacit approval to enter clinical trials. The drug will be asssessed in treating advanced malignant tumors in patients who have failed standard treatments."

Non-US regulatory

Newly added product - P1, Oncology

Pipeline update